Safety of EGb 761® therapy in comorbid patients
https://doi.org/10.21518/2079-701X-2019-1-19-23
Abstract
The article presents data from various studies on the incidence of chronic diseases and conditions among adults, which is a serious public health problem today. The problem of comorbidity in the conditions of demographic aging of the population is highlighted. The results of recent studies on the frequency of side effects depending on the number of drugs taken are presented. It is shown that in old age another problem is the development of cognitive impairment. The results of detection of cognitive disorders among patients of general hospitals are described. Data on the efficacy of the drug application from the standardized extract of ginkgo biloba leaves EGb 761® for prophylaxis and treatment of cognitive disorders are presented. The question of the effect of EGb 761® preparation on blood coagulation properties in comorbid patients taking antiagregants and anticoagulants was considered.
About the Author
N. V. Pizova
Federal State Budgetary Educational Institution of Higher Education «Yaroslavl State Medical University» of the Ministry of Health of the
Russian Federation
Russian Federation
Dr. of Sci. (Med), Professor, Department of Nervous Diseases with Medical Genetics and Neurosurgery of the Federal State Budgetary Educational Institution of Higher Education «Yaroslavl State Medical University» of the Ministry of Health of the Russian Federation
Russian Federation
Dr. of Sci. (Med), Professor, Department of Nervous Diseases with Medical Genetics and Neurosurgery of the Federal State Budgetary Educational Institution of Higher Education «Yaroslavl State Medical University» of the Ministry of Health of the Russian Federation
References
1. European Commission. Active ageing. [cited 2015 Jul 28]. Available from: http://ec.europa. eu/social/main.jsp?catId=1062.
2. The World Bank. Population ages 65 and above (% of total) [cited 2015 Jul 28]. Available from: http://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS.
3. Wilson P.W., D’Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation. 1998 May;97(18):1837–1847.
4. McPherson K., Steel C.M., Dixon J.M. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ. 2000 Sep;321(7261):624–628.
5. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 May;27(5):1047–1053.
6. National Council on Aging. Fact Sheet – healthy aging. [Accessed July 21 2015];2015 https://www.ncoa.org/wpcontent/uploads/ FactSheet_HealthyAging.pdf.
7. Jacob L., Breuer J., Kostev K. Prevalence of chronic diseases among older patients in German general practices. Ger Med Sci. 2016 Mar 3;14:Doc03.
8. Верткин А.Л., Зайратьянц О.В., Вовк Е.И. Окончательный диагноз. М., 2008. [A.L. Vertkin, O.V. Zairatyants, E.I. Vovk Final diagnosis. М., 2008.] (In Russ).
9. Lehnert T., Heider D., Leicht H., Heinrich S., Corrieri S., Luppa M., Riedel-Heller S., König H.H. Review: health care utilization and costs of elderly persons with multiple chronic conditions. Med Care Res Rev. 2011 Aug;68(4):387– 420.
10. Lankarani M.M., Assari S. Association between number of comorbid medical conditions and depression among individuals with diabetes; race and ethnic variations. J. Diabetes Metab. Disord. 2015;14(56):8.
11. Assari S. Cross-county variation in additive effects of socio-economics, health behaviors, and comorbidities on subjective health of patients with diabetes. J. Diabetes Metab. Disord. 2014;13(36):11.
12. Assari S., Lankarani M.M., Ahmadi K. Comorbidity influences multiple aspects of well-being of patients with ischemic heart disease. Int. Cardiovasc. Res. J. 2013;7(4):118–123.
13. Baumeister H., Balke K., Harter M. Psychiatric and somatic comorbidities are negatively associated with quality of life in physically ill patients. J. Clin. Epidemiol. 2005;58:1090–1100.
14. Diederichs C., Berger K., Bartels D.B. The measurement of multiple chronic diseases — a systematic review on existing multimorbidity indices. J. Gerontol. 2010;66A(3):301–311.
15. Prybys K.M., Melville K.A., Hanna J.R. Polypharmacy in the elderly: clinical challenges in emergency practice. Part I: overview, etiology, and drug interactions. Emerg Med Rep. 2002;1:145–51.
16. Reason B., Terner M., Moses McKeag A., Tipper B., Webster G. The impact of polypharmacy on the health of Canadian seniors. Fam Pract. 2012;29(4):427–32.
17. Hu T., Dattani N.D., Cox K.A., Au B., Xu L., Melady D., Jaakkimainen L., Jain R., Charles J. Effect of comorbidities and medications on frequency of primary care visits among older patients. Can Fam Physician. 2017 Jan;63(1):45-50.
18. Vogeli C., Shields A.E., Lee T.A., Gibson T.B., Marder W.D., Weiss K.B., Blumenthal D. Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. J Gen Intern Med. 2007 Dec;22 Suppl 3:391–395.
19. Wolff J.L., Starfield B., Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002 Nov;162(20):2269–2276.
20. Bickel H., Hendlmeier I., Heßler J.B., Junge M.N., Leonhardt-Achilles S., Weber J., Schäufele M. The Prevalence of Dementia and Cognitive Impairment in Hospitals. Dtsch Arztebl Int. 2018 Nov 2;115(44):733-740.
21. Abdel-Kader R., Hauptmann S., Keil U., et al. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761®). Pharmacol Res. 2007;56(6):493–502.
22. Tchantchou F., Xu Y., Wu Y., Christen Y., Luo Y. EGb 761® enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer’s disease. FASEB J. 2007;21(10):2400–2408.
23. Wu Y., Wu Z., Butko P., et al. Amyloid-β-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761® and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci. 2006;26(50):13102–13113.
24. Költringer P., Langsteger W., Ober O. Dosedependent hemorheological effects and microcirulatory modifications following intravenous administration of Ginkgo biloba special extract EGb 761. Clin Hemorheol. 1995;15(4):649–656.
25. Mehlsen J., Drabaek H., Wiinberg N., Winther K. Effects of a Ginkgo biloba extract on forearm haemodynamics in healthy volunteers. Clin Physiol Fund Imaging. 2002;22:375-378.
26. Diamond B.J., Shiflett S.C., Feiwel N., Matheis R.J., Noskin O., Richards J.A., Schoenberger N.E. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabii. 2000;81:663-678.
27. Liebgott T., Miollan M., Berchadsky Y., Drieu K., Culcasi M., Pietri S. Complementary cardioprotective effects of flavonoid metabolites and terpenoid constituents of Ginkgo biloba extract (EGb 761) during ischemia and reperfusion. Basic Res Cardiol. 2000;95:368-377.
28. Akiba S., Kawauchi T., Oka T., Hashizume T., Sato T. Inhibitory effect of the leaf extract of Ginkgo biloba L on oxidative stress-induced platelet aggregation. Biochem Mol Biol Int. 1998;46:1243-1248.
29. Chung K.F., Dent G., McCusker M., Guinot P., Page C.P., Barnes P.J. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet. 1987;1:248-251.
30. Guinot P., Caffrey E., Lambe R., Darragh A. Tanakan inhibits platelet« acth/ating-factor induced platelet aggregation in healthy male volunteers. Haemostasis. 1989;19:219-223.
31. Kudolo G.B., Dorsey S., Blodgett J. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and type 2 diabetic subjects. Thromb Res. 2002;108:151-160.
32. Baf Dit Sollier C., Caplain H., Drouet L. No alteration in platelet function or coagulation induced by EGb761 in a controlled study. Clin Lab Haematol. 2003;25:251-253.
33. Braquet P. Cedemin, a Ginkgo biloba extract, should not be considered as a PAF antagonist [response]. Am J Gastroenterol. 1993;88:2138.
34. Koch E. Inhibition of platelet activating factor (PAR-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomedicine. 2005;12:10- 16.
35. Kohler S., Funk P., Weser M. Influence of a 7-day treatment with Ginkgo biloba special extract EGb 761 on bleeding time and coagulation: a randomized, placebo-controlled, double- blind study in heafthy volunteers. Blood Coagul Fibrinolysis. 2004;15:303-309.
36. Dos Santos-Neto L., de Vilhena Toledo M., Medeiros-Souza P., de Souza G. The use of herbal medicine in Alzheimer’s disease-a systematic review. Evid Based Complement Alternat Med. 2006;3:4:441-445.
37. Bohlken J. Anti-dementia preparations compared. Der Allgemeinarzt. 2003;19:1446-1448.
38. Rowin J., Lewis S.L. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology.
39. ;46:1775–6.
40. Bone K.M. Potential interaction of Ginkgo biloba leaf with antiplatelet or anticoagulant drugs: what is the evidence? Mol Nutr Food Res. 2008;52:764–71.
41. Gardner C.D., Zehnder J.L., Rigby A.J., Nicholus J.R., Farquhar J.W. Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial. Blood Coagulation and Fibrinolysis. 2007;18:787-793.
42. Kellermann A.J., Kloft C. Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy. 2011 May;31(5):490-502.
Review
For citations:
Pizova NV. Safety of EGb 761® therapy in comorbid patients. Meditsinskiy sovet = Medical Council. 2019;(1):19-23. (In Russ.) https://doi.org/10.21518/2079-701X-2019-1-19-23
Views:
916
Email this article 